Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Mofezolac is an inhibitor of COX-1 (IC50 = 14 nM).1 It is selective for COX-1 over COX-2 (IC50 = 440 nM). Mofezolac (1 µg/ml) protects against LPS-induced cell death in BV-2 microglia. In vivo, mofezolac (6 mg/kg, i.p.) reduces hippocampal microglial activation and prostaglandin E2 (PGE2; Item No. 14010) production in a mouse model of LPS-induced neuroinflammation. It reduces phenylquinone-induced writhing in a mouse model of acute pain.2 Dietary administration of mofezolac (1,200 ppm) reduces the number of aberrant crypt foci and tumors in a rat model of beef tallow diet-induced colon carcinogenesis.3
WARNING This product is not for human or veterinary use.
1. Highly selective cyclooxygenase-
2. Analgesic effect of mofezolac, a non-
3. Chemopreventive effect of mofezolac on beef tallow diet/azoxymethane-